drug

ASP2767

1 story · latest Aug 18, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Astellas Pharma

Timeline

Astellas registers Phase 1/2 gene therapy trial for ASP2767 in glaucoma optic nerve damage

Aug 18Trial updateASP2767 Astellas Pharma

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.